Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization

Vaccine

Volumn 30, Issue 28, 2012, Pages 4135-4143

  Liu, Lianxing ^a,b,c   Hao, Yanling ^a   Luo, Zhenwu ^a,b   Huang, Yang ^a   Hu, Xintao ^a   Liu, Ying ^a   Shao, Yiming ^a,b  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b WUHAN INSTITUTE OF VIROLOGY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Heterologous prime boost immunization; HIV; Neutralizing antibody; Vaccine

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 145; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLADISTICS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GUINEA PIG; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS GENE; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC VECTORS; GUINEA PIGS; HIV-1; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT; VACCINIA VIRUS;

EID: 84861685573     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.075     Document Type: Article

References (46)

1. Miller C.J., Li Q., Abel K., Kim E.Y., Ma Z.M., Wietgrefe S., et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. Journal of Virology 2005, 79(July (14)):9217-9227.
2. Milush J.M., Kosub D., Marthas M., Schmidt K., Scott F., Wozniakowski A., et al. Rapid dissemination of SIV following oral inoculation. AIDS (London, England) 2004, 18(December (18)):2371-2380.
3. Abel K., Pahar B., Van Rompay K.K., Fritts L., Sin C., Schmidt K., et al. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. Journal of Virology 2006, 80(July (13)):6357-6367.
4. Weiler A.M., Li Q., Duan L., Kaizu M., Weisgrau K.L., Friedrich T.C., et al. Genital ulcers facilitate rapid viral entry and dissemination following intravaginal inoculation with cell-associated simian immunodeficiency virus SIVmac239. Journal of Virology 2008, 82(April (8)):4154-4158.
5. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., et al. Diversity considerations in HIV-1 vaccine selection. Science (New York, NY) 2002, 296(June (5577)):2354-2360.
6. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Research and Human Retroviruses 1994, 10(April (4)):359-369.
7. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329(August (5993)):856-861.
8. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326(October (5950)):285-289.
9. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira T.Y., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333(September (6049)):1633-1637.
10. Diskin R., Scheid J.F., Marcovecchio P.M., West A.P., Klein F., Gao H., et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011, 334(December (6060)):1289-1293.
11. Corti D., Langedijk J.P., Hinz A., Seaman M.S., Vanzetta F., Fernandez-Rodriguez B.M., et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010, 5(January (1)):e8805.
12. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. Journal of Virology 2004, 78(December (23)):13232-13252.
13. Trkola A., Kuster H., Rusert P., Joos B., Fischer M., Leemann C., et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nature Medicine 2005, 11(June (6)):615-622.
14. Zhang P.F., Cham F., Dong M., Choudhary A., Bouma P., Zhang Z., et al. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(June (24)):10193-10198.
15. Chakrabarti B.K., Kong W.P., Wu B.Y., Yang Z.Y., Friborg J., Ling X., et al. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. Journal of Virology 2002, 76(June (11)):5357-5368.
16. Binley J., Moore J.P. HIV-cell fusion. The viral mousetrap. Nature 1997, 387(May (6631)):346-348.
17. LaCasse R.A., Follis K.E., Trahey M., Scarborough J.D., Littman D.R., Nunberg J.H. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science (New York, NY) 1999, 283(January (5400)):357-362.
18. Liu L., Wan Y., Xu J., Huang X., Wu L., Liu Y., et al. Immunogenicity comparison between codon optimized HIV-1 CRF BC_07 gp140 and gp145 vaccines. AIDS Research and Human Retroviruses 2007, 23(November (11)):1396-1404.
19. Wan Y., Wu L., Liu L., Xu J., Liu Y., Liu Y., et al. Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines. Vaccine 2007, 25(June (26)):4949-4959.
20. Gu S., Huang T., Miao Y., Ruan L., Zhao Y., Han C., et al. A preliminary study on the immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing Epstein--Barr virus membrane antigen. Chinese Medical Sciences Journal 1991, 6(4):241-243.
21. Guo K.J., Ruan L., Wang X.J., Yao Y., Liu C.B., Ren Y.H., et al. The immunological effect of recombinant vaccinia virus (VMS11HAV25) expressing hepatitis A antigen in humans. Chinese Journal of Microbiology and Immunology 1992, 12(3):137-140.
22. Reitter J.N., Means R.E., Desrosiers R.C. A role for carbohydrates in immune evasion in AIDS. Nature Medicine 1998, 4(June (6)):679-684.
23. Ly A., Stamatatos L. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. Journal of Virology 2000, 74(August (15)):6769-6776.
24. Koch M., Pancera M., Kwong P.D., Kolchinsky P., Grundner C., Wang L., et al. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 2003, 313(September (2)):387-400.
25. Malenbaum S.E., Yang D., Cavacini L., Posner M., Robinson J., Cheng-Mayer C. The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. Journal of Virology 2000, 74(December (23)):11008-11016.
26. Fouts T., Godfrey K., Bobb K., Montefiori D., Hanson C.V., Kalyanaraman V.S., et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(September (18)):11842-11847.
27. Fouts T.R., Tuskan R., Godfrey K., Reitz M., Hone D., Lewis G.K., et al. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. Journal of Virology 2000, 74(December (24)):11427-11436.
28. Hoffman T.L., LaBranche C.C., Zhang W., Canziani G., Robinson J., Chaiken I., et al. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(May (11)):6359-6364.
29. Liu L., Wan Y., Wu L., Sun J., Li H., Li H., et al. Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine. Retrovirology 2010, 7(September):71.
30. Belshe R.B., Gorse G.J., Mulligan M.J., Evans T.G., Keefer M.C., Excler J.L., et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS (London, England) 1998, 12(December (18)):2407-2415.
31. Belshe R.B., Graham B.S., Keefer M.C., Gorse G.J., Wright P., Dolin R., et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. Journal of the American Medical Association 1994, 272(August (6)):475-480.
32. Graham B.S., McElrath M.J., Connor R.I., Schwartz D.H., Gorse G.J., Keefer M.C., et al. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. The Journal of Infectious Diseases 1998, 177(February (2)):310-319.
33. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The Journal of Infectious Diseases 1996, 173(February (2)):340-348.
34. Matthews T.J. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Research and Human Retroviruses 1994, 10(June (6)):631-632.
35. Evans L.A., Thomson-Honnebier G., Steimer K., Paoletti E., Perkus M.E., Hollander H., et al. Antibody-dependent cellular cytotoxicity is directed against both the gp120 and gp41 envelope proteins of HIV. AIDS (London, England) 1989, 3(May (5)):273-276.
36. Gnann J.W., Nelson J.A., Oldstone M.B. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. Journal of Virology 1987, 61(August (8)):2639-2641.
37. Lorizate M., Huarte N., Sáez-Cirión A., Nieva J.L. Interfacial pre-transmembrane domains in viral proteins promoting membrane fusion and fission. Biochimica et Biophysica Acta 2008, 1778(July-August (7-8)):1624-1639.
38. Montero M., van Houten N.E., Wang X., Scott J.K. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiology and Molecular Biology Reviews 2008, 72(March (1)):54-84.
39. Veiga A.S., Pattenden L.K., Fletcher J.M., Castanho M.A., Aguilar M.I. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems. Chembiochem 2009, 10(April (6)):1032-1044.
40. Franquelim H.G., Chiantia S., Veiga A.S., Santos N.C., Schwille P., Castanho M.A. Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes. AIDS 2011, 25(February (4)):419-428.
41. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Medicine 1998, 4(April (4)):397-402.
42. Hanke T., Blanchard T.J., Schneider J., Hannan C.M., Becker M., Gilbert S.C., et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998, 16(March (5)):439-445.
43. Hel Z., Tsai W.P., Thornton A., Nacsa J., Giuliani L., Tryniszewska E., et al. Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. Journal of Immunology 2001, 167(December (12)):7180-7191.
44. Zhao K., Zhang Y.H., Li H.M. Medical Biology Product 1995, People's Medical Publishing House, Beijing. 2nd ed.
45. Shao Y.M., Liu Y., Xu J., Li T.S., Liu Y., Hao Y.L., et al. AIDS vaccine research, from basic research to clinical study. Selected Presentations from the 2011 Sino-American Symposium on Clinical and Translational Medicine 2011, 44-45. S. Sanders (Ed.).
46. Dai K.F., Liu Y., Liu M.J., Xu J.Q., Huang W., Huang X.G., et al. Pathogenicity and immunogenicity of recombinant Tiantan vaccinia virus with deleted C12L and A53R genes. Vaccine 2008, 26(September (39)):5062-5071.